DocWire News Editors

DocwireNews

Patients with coronavirus disease 2019 (COVID-19) may develop acute kidney disease (AKI). The United Kingdom National Institute for Health and Care Excellence (NICE) developed guidelines for the management of AKI in patients with COVID-19. Thomas Phillips, PhD, and colleagues at the University Hospital Southampton NHS Foundation Trust conducted an analysis to examine the local patient-level COVID-19 Hospitalisation in England Surveillance System database to identify potential risk factors for AKI versus the guidelines. Results were reported during a virtual poster session at ASN Kidney Week 2020 in a poster titled COVID-19 AKI: Risk factors and Markers of Disease from a Large UK Cohort.The analysis included data on 564 COVID-19-positive admissions between March 7, 2020, and May 24, 2020, at the University Hospital Southampton. Consistent with NICE guidance, RIFLE (risk, injury, failure, loss of kidney function, and end-stage kidney disease) and AKIN (Acute Kidney Injury Network) criteria were used to stage AKI. Data were analyzed using X2, t-test, Mann-Whitney U test, and logistic regression.Of the 564 patients with COVID-19, 31% (n=177) developed AKI. At peak, 61% (n=108) had stage 1 chronic kidney disease, 24% (n=42) had stage 2 AKI, and 15% (n=27) had stage 3 AKI. There were no significant differences between the cohorts in White versus non-White race/ethnicity, sex, obesity, or anti-COVID-19 treatment. Of the patients in the AKI cohort, 44% died compared with 19% in the non-AKI group (P&lt;.001). There were associations between AKI and admission to the intensive care unit (ICU), (27% vs 10%; P&lt;.001), the need for noninvasive ventilation (13% vs 4%; P&lt;.001), and the need for invasive ventilation (14% vs 4%; P&lt;.001).In the AKI group, compared with the non-AKI group, patients more commonly had a history of diabetes (18% vs 8%), hypertension (47% vs 34%), chronic respiratory disease (25% vs 15%), and chronic heart disease (25% vs 15%). There was an association between increased age and AKI (P=.02), as well as a positive correlation between length of stay and AKI stage (P&lt;.001).In patients in the AKI group, and increasing with AKI stage, peak levels of ferritin, D-dimer, C-reactive protein, high sensitivity troponin-I, neutrophil count, and total white count were all significantly raised compared with the non-AKI group. In multivariable analysis of first clinical observations, the most significant predictors of AKI were neutrophil count, hemoglobin, D-dimer, and albumin: specificity 88.7%, sensitivity 43.6%.In conclusion, the researchers said, &ldquo;AKI is a frequent complication of COVID-19, and we identified similar risk factors to those in the NICE guidelines. In addition, we found hypertension and chronic respiratory disease to increase risk of AKI whilst ethnicity, gender, obesity, and COVID-19 treatments did not. Furthermore, AKI was associated with increased mortality, ICU admissions, and length of stay, concordant with previous studies. These data also point to several biomarkers as possible predictors of AKI development and severity. Further analysis of the data is ongoing.&rdquo;Read more here: <a href="https://www.asn-online.org/education/kidneyweek/2020/program-abstract.aspx?controlId=3445313">https://www.asn-online.org/education/kidneyweek/2020/program-abstract.aspx?controlId=3445313</a>Source: Phillips T, Leggatt G, Stammers M, et al. COVID-19 AKI: Risk factors and markers of disease from a large UK cohort. Abstract of a poster presented at the American Society of Nephrology virtual Kidney Week 2020 (PO0666), October 22, 2020.

Bradley Marder, MD

Joel M. Topf, MD, FACP

Gout Studies: Transplant Waitlisting and Bone Erosion

NKF Spring Clinical Meetings 2025

Jayme Locke, MD, MPH

The Promise of Xenotransplantation

Leah Lawrence

Real-World Data Backs Invasive DFS as Surrogate Endpoint for OS in EBC

HR Breast Cancer

Latest News

Risk Factors for AKI in Patients with COVID-19

ASN Kidney Week 2020

Patients with coronavirus disease 2019 (COVID-19) may develop acute kidney disease (AKI). The United Kingdom National Institute for Health and Care Excellence (NICE) developed ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe